AstraZeneca, the U.K.-based pharmaceuticals giant, said on Tuesday that it would pause the clinical trial of the coronavirus vaccine it is developing with the University of Oxford after a British subject became ill. The decision will affect the so-called Phase 3 trials the company just started by enrolling 30,000 volunteers in the U.S., after recruiting 10,000 subjects in the U.K. over the summer.
- The U.K. company’s shares fell more than 1% Wednesday on the news, in generally positive European markets as measured by the Stoxx 600 SXXP, +1.62% index. Read:AstraZeneca stock falls as drugmaker pauses vaccine trial after volunteer’s ‘unexplained illness’ - Big Pharma’s unusual statement comes amid concerns that the Trump administration may try to push one or more COVID-19 vaccines through the approval process, such as by granting an emergency-use authorization sooner than science might dictate, in order to gain an advantage in the presidential election.
American Small Businesses are dying at a greater rate than people from covid. The difference is they leave families with nowhere safe to go.
tickergod $AZN price